Derivative exercise or conversion — not an open-market buy.
Loading…
Traded Nov 4, 2025 · Filed Nov 5, 2025
Cytokinetics's Research & Development sold $137K of Cytokinetics shares. It happened by itself, for taxes or pay.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$136,667
Shares × reported transaction price
89 days after results of Aug 7, 2025, 1 day before results of Nov 5, 2025
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Filing box checked: sold under a Rule 10b5-1 plan
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +11.4% | +0.9% | +10.5% |
| 30 days | +10.9% | +1.2% | +9.8% |
| 90 days | +9.4% | +1.8% | +7.6% |
| 180 days | +11.6% | +6.0% | +5.6% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.